Inventor · disambiguated record
Kang Le
Also filed as: LE KANG
19 granted patents·9 pending applications·141 citations·filing 2001–2025
94Inventor score
Top patents by PatentIndex Score
28 records- 0196US11603365B2Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2020·Granted Mar 14, 2023·4 cites·30 claims
- 0296US11370786B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Jun 28, 2022·6 cites·17 claims
- 0395US11958849B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2022·Granted Apr 16, 2024·2 cites·12 claims
- 0495US10899740B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2019·Granted Jan 26, 2021·8 cites·15 claims
- 0594US12186324B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2021·Granted Jan 7, 2025·3 cites·26 claims
- 0694US10766892B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2019·Granted Sep 8, 2020·9 cites·26 claims
- 0794US10150753B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2016·Granted Dec 11, 2018·7 cites·15 claims
- 0893US9809588B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Granted Nov 7, 2017·15 cites·27 claims
- 0992US10344025B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2017·Granted Jul 9, 2019·12 cites·11 claims
- 1089US11058688B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jul 13, 2021·3 cites·41 claims
- 1186US6583288B2Hydantoin-containing glucokinase activatorsHOFFMANN LA ROCHE·Filed 2001·Granted Jun 24, 2003·29 cites·40 claims
- 1286US2024360121A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1385US10899769B2Imidazopiperazinone inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jan 26, 2021·3 cites·26 claims
- 1485US10093664B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2017·Granted Oct 9, 2018·4 cites·24 claims
- 1585US6784298B2Hydantoin-containing glucokinase activatorsHOFFMANN LA ROCHE·Filed 2003·Granted Aug 31, 2004·28 cites·8 claims
- 1684US12252480B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2023·Granted Mar 18, 2025·0 cites·10 claims
- 1783US11560366B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Jan 24, 2023·1 cites·24 claims
- 1881US7645773B2Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenaseHOFFMANN LA ROCHE·Filed 2007·Granted Jan 12, 2010·6 cites·17 claims
- 1980US2025127792A1Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 2075US10428057B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2018·Granted Oct 1, 2019·1 cites·46 claims
- 2175US2025250253A1Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2025·Application pending·0 cites
- 2272US2022267311A1Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of diseaseUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2365US2025049809A1Inhibitors of mutant idh1 and idh2UNIV TEXAS·Filed 2024·Application pending·0 cites
- 2450US2025243209A1Heterocycles as modulators of nsd activityUNIV TEXAS·Filed 2025·Application pending·0 cites
- 2544US9422332B2Azaheterocycles as BIR2 and/or BIR3 inhibitorsHOFFMANN LA ROCHE·Filed 2013·Granted Aug 23, 2016·0 cites·23 claims
- 2644US2019382396A1Salts of bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of diseaseUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2740US2018057507A1Inhibitors of dual leucine zipper (dlk) kinase for the treatment of diseaseUNIV TEXAS·Filed 2017·Application pending·0 cites
- 2835US2016002248A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kang Le files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →